AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug

NCT Number	NCT06911333
Lead Sponsor	Avelos Therapeutics Inc.
Conditions	Solid Tumor, Adult, Tumor, Solid, Solid Tumor, Solid Tumor, Unspecified, Adult, Solid Tumor Cancer, Solid Tumors Refractory to Standard Therapy, Solid Tumor in Advanced Stage
Enrollment	36 participants
Start Date	2025-03-11
Primary Completion	2029-06-30 (estimated)
Study Completion	2030-02-20 (estimated)
Updated on ClinicalTrials.gov	2025-04-04